• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

More Research Is Needed on Lifestyle Behaviors That Influence Progression of Parkinson's Disease
This article highlights some of these challenges in the design of lifestyle studies in PD, and suggests a more coordinated international effort is required, including ongoing longitudinal observational studies. In combination with pharmaceutical treatments, healthy lifestyle behaviors may slow the progression of PD, empower patients, and reduce disease burden. For optimal care of people with PD, it is important to close this gap in current knowledge and discover whether such associations exist. Introduction Parkinson's disease (PD) is an age-related complex progressive neurodegenerative disorder, with key p...
Source: Frontiers in Neurology - April 29, 2019 Category: Neurology Source Type: research

Intracranial Hemorrhage Detection Software Receives FDA Clearance
“AI and machine learning are going to transform healthcare, as they have virtually every other industry they have touched,” said Gene Saragnese, chairman and CEO of MaxQ AI in an interview with MD+DI. “Our world is surrounded by algorithms that present information, but one place it’s been lacking is healthcare.” MaxQ AI is doing its best to remedy that deficiency, starting with software that can detect intracranial hemorrhage (ICH). The company’s recently FDA-cleared Accipio Ix is used with noncontrast co...
Source: MDDI - November 17, 2018 Category: Medical Devices Authors: Susan Shepard Tags: Digital Health Source Type: news

Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease
In this study, we used a well-validated visual assessment to clinically rate scans as being amyloid positive or negative (38). As there is not an accepted threshold based on standardized centiloid reference regions, we defined an amyloid positivity centiloid cut-off threshold in our sample. Our cut-off (CL = 31.3, SUVR = 1.21) corresponds well to the estimated value proposed by Rowe and colleagues (34) in the context of AD (CL = 25–30), however our estimated threshold may be biased by the low number of Aβ positive patients. Our results suggest a lower prevalence of amyloid-positive PDD individuals than in ...
Source: Frontiers in Neurology - April 23, 2019 Category: Neurology Source Type: research